NovalGen’s proprietary ground-breaking autoregulation technology platform enables the maximum efficacy to be unleashed from a therapy whilst ensuring a manageable safety profile by limiting life threatening toxicities.

The technology utilises biosensors that, when applied to therapeutic molecules, allow the drug to act on the targeted biological system and correct the pathological condition. The built in biosensor constantly monitors for toxicity cue within the pathological milieu such that when there is risk of life threatening toxicity, the molecule “switches” itself off thus limiting the severity and duration of any adverse events.

This technology can be applied to a multitude of antibodies, protein-based therapeutics, as well as cellular therapies. Our next generation of  T cell engagers (TCEs, e.g. NVG-222), factor VIII mimetic and CAR-T therapy all incorporate such biosensors to enhance safety and widen the therapeutic window. This will enable the highest efficacious dosing regimens to be realised whilst crucially maintaining patient safety.

NVG-222 will be the first ever therapy in the clinic to possess such a capability. NovalGen’s autoregulation platform has the potential to truly revolutionise treatment for a range of disorders.

More in this section

Key capabilities

Novalgen is a fully integrated company capable of developing breakthrough therapies.

Read more

Our technologies

We are changing the paradigm of cancer therapy with our immunotherapy technology.

Read more